Consolidative use of radiotherapy to block oligoprogression in patients with metastatic melanoma on Systemic Therapy (CURB-Melanoma) - a single arm, phase 2 clinical trial - Takeaways - MDSpire

Consolidative use of radiotherapy to block oligoprogression in patients with metastatic melanoma on Systemic Therapy (CURB-Melanoma) - a single arm, phase 2 clinical trial

  • By

  • Oded Icht

  • Alexander Sun

  • Philip Wong

  • Andrew McPartlin

  • Thiago Pimentel Muniz

  • Anna Spreafico

  • Samuel D. Saibil

  • J. Nicholas Lukens

  • Sana D Karam

  • John De Almeida

  • Marcus O. Butler

  • C. Jillian Tsai

  • July 6, 2026

  • 0 min

Share

  • 1

    The CURB-Melanoma trial investigates SBRT's effect on progression-free survival in metastatic melanoma patients with oligoprogression.

  • 2

    Eligible patients have ≤10 extracranial oligoprogressive sites while on first-line systemic therapy, defined by modified RECIST 1.1 or PERCIST.

  • 3

    The primary endpoint is progression-free survival, with secondary endpoints including overall survival, treatment tolerance, and quality of life.

  • 4

    The trial aims to enroll 52 patients over 12 months, with an additional 24 months of follow-up for comprehensive data collection.

  • 5

    Exploratory analyses will include circulating tumor DNA and immune profiling to assess treatment effects and patient responses.

Original Source(s)

Consolidative use of radiotherapy to block oligoprogression in patients with metastatic melanoma on Systemic Therapy (CURB-Melanoma) - a single arm, phase 2 clinical trial

  • by Oded Icht, Alexander Sun, Philip Wong, Andrew McPartlin, Thiago Pimentel Muniz, Anna Spreafico, Samuel D. Saibil, J. Nicholas Lukens, Sana D Karam, John De Almeida, Marcus O. Butler, C. Jillian Tsai

  • July 6, 2026

Related Content

Artificial intelligence in three-dimensional total-body photography for skin cancer surveillance

A review on in-silico analysis of immune cell trafficking and interactions with the tumour microenvironment

Advances in the multimodal management of central nervous system solitary fibrous tumors